info@synchemia.com | sales@synchemia.com 
9766925136 
Cevimeline
Cevimeline | CAS NO: 107233-08-9 , Cevimeline (brand name Evoxac) is an FDA-approved, oral cholinergic agonist used to treat dry mouth (xerostomia) in patients with Sjögren’s syndrome. By acting on M3 muscarinic receptors in salivary glands, it increases saliva production, improving swallowing and speaking. The typical dosage is 30 mg three times daily.
We are the Synchemia Research Chemical specializes in manufacturing and supplying of Cevimeline impurities that meet specific pharmacopeial standards (EP/BP/USP/IP) as well as process-related impurities. Cevimeline (brand name Evoxac) is an FDA-approved, oral cholinergic agonist used to treat dry mouth (xerostomia) in patients with Sjögren’s syndrome. By acting on M3 muscarinic receptors in salivary glands, it increases saliva production, improving swallowing and speaking. The typical dosage is 30 mg three times daily. Buy Reliable and High-Purity Cevimeline Impurities, Delivered by Synchemia Research Chemicals.
Download catalogue
Pharmaceutical Reference Standards
| CAT No | SRC-C2121 |
| CAS No | 107233-08-9 |
| Mol.F. | C10H17NOS |
| Mol.Wt. | 199.3 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2122 |
| CAS No | 61573-79-3 |
| Mol.F. | C8H15NO2 |
| Mol.Wt. | 157.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2123 |
| CAS No | 107220-29-1 |
| Mol.F. | C10H17NOS : HCl |
| Mol.Wt. | 199.3 : 36.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2124 |
| CAS No | 469890-14-0 |
| Mol.F. | C10H17NO2S |
| Mol.Wt. | 215.3 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2125 |
| CAS No | NA |
| Mol.F. | C27H29NOS |
| Mol.Wt. | 415.6 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2126 |
| CAS No | 61573-79-3 |
| Mol.F. | C8H15NO2 : HCl |
| Mol.Wt. | 157.2 : 36.5 g/mol |
| INV STATUS | IN STOCK |
| CAT No | SRC-C2127 |
| CAS No | 107220-26-8 |
| Mol.F. | C8H15NOS |
| Mol.Wt. | 173.3 g/mol |
| INV STATUS | IN STOCK |
| CAT No | SRC-C2128 |
| CAS No | NA |
| Mol.F. | C10H17NO2S |
| Mol.Wt. | 215.3 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2129 |
| CAS No | 124751-37-7 |
| Mol.F. | C10H17NO2S |
| Mol.Wt. | 215.3g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2130 |
| CAS No | 124751-36-6 |
| Mol.F. | C10H17NO2S |
| Mol.Wt. | 215.3g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2131 |
| CAS No | NA |
| Mol.F. | C14H20N2O |
| Mol.Wt. | 232.3g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2132 |
| CAS No | 1434122-45-8 |
| Mol.F. | C16H28N2O2S |
| Mol.Wt. | 312.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2133 |
| CAS No | NA |
| Mol.F. | C10H17NO3S |
| Mol.Wt. | 231.3g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2134 |
| CAS No | NA |
| Mol.F. | C20H32N2O4S2 |
| Mol.Wt. | 428.6g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2135 |
| CAS No | 1434122-43-6 |
| Mol.F. | C16H28N2O2S2 |
| Mol.Wt. | 344.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-C2136 |
| CAS No | NA |
| Mol.F. | C18H32N2O2S2 |
| Mol.Wt. | 372.6g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
Let’s advance your research together.
Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.
